Boehringer Ingelheim to share latest oncology pipeline updates across multiple cancer types at ESMO Congress 2025

At the European Society for Medical Oncology (ESMO) Congress 2025, Boehringer Ingelheim will present new data from across its robust oncology pipeline, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). With new first-line data for HERNEXEOS^® (zongertinib tablets) featured in the NSCLC Proffered Paper session and a total of ten abstracts to be presented, these updates reinforce Boehringer’s oncology foothold and commitment to making an unprecedented impact on the lives of those affected by cancer through innovative research.

“Our oncology pipeline is at its strongest throughout its long history. Spearheaded by zongertinib, our targeted therapy for HER2-mutant NSCLC, we are making headway towards our goal of resetting the benchmark in certain types of cancer. Followed by our novel T-cell engager obrixtamig, which we’re investigating in SCLC and extrapulmonary neuroendocrine carcinomas and many other cell-directed therapies, we are breaking new ground by focusing on the most hard-to-treat cancer types,” said Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim. “Cancer is and will be one of humanity’s greatest challenges for decades to come. This is why Boehringer is deeply committed to continue to deliver innovative personalized approaches and breakthrough therapies in this field.”

Accelerating targeted treatment route in HER2 (ERBB2)-mutant NSCLC 
Late-breaking data from the Beamion LUNG-1 trial with HERNEXEOS given as first-line therapy in HER2 (ERBB2)-mutant advanced NSCLC will be presented during the Proffered Paper session on Friday, October 17, at 4:35 PM CEST.

This presentation follows the recent approval of HERNEXEOS for patients with previously treated HER2 (ERBB2)-mutant advanced NSCLC in the U.S. (accelerated), China (conditional), and Japan. Zongertinib was recently granted Breakthrough Therapy Designation by the Food and Drug Administration (FDA) in the U.S. and by China’s Center for Drug Evaluation (CDE) for first-line treatment of adult patients with unresectable/metastatic NSCLC whose tumors have HER2 TKD activating mutations.

Expanding the treatment landscape in SCLC
Exploring the potential of DLL3-targeted immunotherapy in transforming the treatment of neuroendocrine carcinomas, Boehringer will present data from the Phase I DAREON^®-8 trial in a mini oral presentation on Saturday, October 18, at 4:40 PM CEST. The presentation will include an update on a novel T-cell engager, obrixtamig, as a combination therapy with standard of care (chemotherapy and atezolizumab) in extensive-stage small cell lung carcinoma (ES-SCLC), showcasing its potential as first-line treatment for patients with SCLC.

Boehringer’s growing oncology portfolio
Beyond the lung cancer space, Boehringer Ingelheim will also present updated data from immuno-oncology therapies, including from Phase Ia STING trial for patients with advanced solid tumors. In addition to this, real-world outcomes from the VARGADO study in NSCLC will also be shared and a trial in progress that is open for enrollment to research the safety and efficacy of SIRPa ‘371 combined with pembrolizumab as first-line treatment in patients with head and neck cancer will be presented. This research highlights Boehringer’s commitment to evolving the landscape in next-generation cancer therapies, striving towards improving the outcomes for those affected by cancer.

View data from Boehringer’s oncology pipeline to be presented at ESMO HERE.